

Neil Fleshner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9688366/publications.pdf>

Version: 2024-02-01

102
papers

2,556
citations

257450

24
h-index

206112

48
g-index

104
all docs

104
docs citations

104
times ranked

4022
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745. | 21.4 | 395 |
| 2 | Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. <i>Journal of Clinical Oncology</i> , 2013, 31, 3069-3075. | 1.6 | 240 |
| 3 | Epidemiology and Prevention of Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 877-892. | 5.4 | 190 |
| 4 | A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674. | 1.9 | 142 |
| 5 | Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. <i>Urology</i> , 2002, 60, 93-97. | 1.0 | 115 |
| 6 | Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. <i>European Urology</i> , 2019, 75, 300-309. | 1.9 | 99 |
| 7 | Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. <i>European Urology</i> , 2020, 77, 311-317. | 1.9 | 99 |
| 8 | Dietary Fat and Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, S19-24. | 0.4 | 83 |
| 9 | Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. <i>Contemporary Clinical Trials</i> , 2007, 28, 763-769. | 1.8 | 67 |
| 10 | EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS. <i>Journal of Urology</i> , 2005, 174, 636-641. | 0.4 | 64 |
| 11 | Prostate cancer prevention. <i>Cancer</i> , 2007, 110, 1889-1899. | 4.1 | 60 |
| 12 | Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. <i>European Urology</i> , 2014, 66, 619-622. | 1.9 | 57 |
| 13 | Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46. | 0.6 | 55 |
| 14 | Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 395-406. | 2.8 | 46 |
| 15 | Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24. | 0.6 | 44 |
| 16 | Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019, 74, 474-482. | 2.9 | 44 |
| 17 | Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093. | 0.4 | 44 |
| 18 | Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045. | 2.7 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids. <i>Scientific Reports</i> , 2015, 4, 4432. | 3.3 | 38 |
| 20 | Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379. | 7.3 | 34 |
| 21 | A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350. | 1.9 | 33 |
| 22 | Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334. | 1.6 | 29 |
| 23 | A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. <i>Clinical Epigenetics</i> , 2018, 10, 147. | 4.1 | 26 |
| 24 | Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018, 1, 238-241. | 5.4 | 25 |
| 25 | Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. <i>Journal of Urology</i> , 2020, 204, 466-475. | 0.4 | 24 |
| 26 | Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , 2017, 120, 76-82. | 2.5 | 23 |
| 27 | Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187. | 0.4 | 22 |
| 28 | Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , 2016, 196, 1645-1650. | 0.4 | 19 |
| 29 | Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. <i>Oncology Letters</i> , 2017, 14, 390-396. | 1.8 | 19 |
| 30 | Germ Cell Testicular Tumors—Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. <i>Urology</i> , 2019, 125, 8-19. | 1.0 | 19 |
| 31 | Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2587-2594. | 4.1 | 16 |
| 32 | Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , 2017, 8, 25928-25941. | 1.8 | 16 |
| 33 | First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029. | 5.0 | 15 |
| 34 | Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25. | 1.6 | 14 |
| 35 | Active surveillance in patients with a PSA >10 ng/mL. <i>Canadian Urological Association Journal</i> , 2014, 8, 702. | 0.6 | 12 |
| 36 | The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 537-545. | 3.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020, 14, E453-E457. | 0.6 | 11 |
| 38 | Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114694. | 5.9 | 11 |
| 39 | Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. <i>Urology</i> , 2019, 134, 24-31. | 1.0 | 10 |
| 40 | Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554. | 2.2 | 10 |
| 41 | An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , 2016, 195, 307-312. | 0.4 | 9 |
| 42 | Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97. | 0.6 | 9 |
| 43 | GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. <i>European Urology Oncology</i> , 2019, 2, 231-238. | 5.4 | 9 |
| 44 | An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 39.e1-39.e9. | 1.6 | 9 |
| 45 | Optimizing screening and management of cardiovascular health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E458-E464. | 0.6 | 9 |
| 46 | Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. <i>Cancers</i> , 2021, 13, 3607. | 3.7 | 9 |
| 47 | Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1187-1194. | 0.4 | 9 |
| 48 | A narrative review of pelvic lymph node dissection in prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 3049-3055. | 1.4 | 9 |
| 49 | Controversies in the management of testicular seminoma. <i>Urologic Oncology</i> , 2002, 20, 227-233. | 1.5 | 8 |
| 50 | Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. <i>Journal of Urology</i> , 2019, 202, 1159-1165. | 0.4 | 8 |
| 51 | Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 416-426. | 0.4 | 8 |
| 52 | Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. <i>Canadian Journal of Urology</i> , 2006, 13 Suppl 3, 3-13. | 0.0 | 8 |
| 53 | Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554. | 4.5 | 8 |
| 54 | Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20. | 1.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96. | 5.4 | 7 |
| 56 | Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , 2020, 204, 476-482. | 0.4 | 7 |
| 57 | Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093. | 0.4 | 6 |
| 58 | The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424. | 0.6 | 6 |
| 59 | The deleterious association between proton pump inhibitors and prostate cancer-specific mortality â€“ a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 622-629. | 3.9 | 6 |
| 60 | Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. <i>Canadian Urological Association Journal</i> , 2015, 9, 14. | 0.6 | 5 |
| 61 | Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. <i>Canadian Urological Association Journal</i> , 2019, 14, 36-41. | 0.6 | 5 |
| 62 | Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients â€“ A Cross Sectional Study. <i>Urology</i> , 2019, 134, 154-162. | 1.0 | 5 |
| 63 | A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?. <i>European Urology Focus</i> , 2021, 7, 506-507. | 3.1 | 5 |
| 64 | A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155. | 1.0 | 5 |
| 65 | Defining high-risk prostate cancer: current status. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 1, 14-7; discussion 94-6. | 0.0 | 5 |
| 66 | The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. <i>Canadian Urological Association Journal</i> , 2021, 15, E623-E629. | 0.6 | 4 |
| 67 | The role of metformin, statins and diet in men on active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 61-69. | 2.2 | 4 |
| 68 | Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with synâ€“or metachronous metastatic disease. <i>Prostate</i> , 2022, 82, 345-351. | 2.3 | 4 |
| 69 | Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2019, 14, E115-E125. | 0.6 | 3 |
| 70 | Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. <i>World Journal of Urology</i> , 2019, 37, 799-804. | 2.2 | 3 |
| 71 | Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. <i>Canadian Urological Association Journal</i> , 2021, 15, E545-E552. | 0.6 | 3 |
| 72 | Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. <i>Canadian Urological Association Journal</i> , 2021, 16, . | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e217-e226. | 1.9 | 3 |
| 74 | Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. <i>Cancers</i> , 2022, 14, 1004. | 3.7 | 3 |
| 75 | Is pathology necessary to predict mortality among men with prostate-cancer?. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 114. | 3.0 | 2 |
| 76 | Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061. | 0.4 | 2 |
| 77 | Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8. | 1.6 | 2 |
| 78 | Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 131-131. | 1.6 | 2 |
| 79 | Have we mis-PRONOUNCED the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 657-658. | 3.9 | 2 |
| 80 | Prostate cancer: chemoprevention update 2005. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 2, 2-4. | 0.0 | 2 |
| 81 | Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. <i>Journal of Endourology</i> , 2022, 36, 1083-1090. | 2.1 | 2 |
| 82 | Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. <i>Proteomics - Clinical Applications</i> , 2009, 3, 347-358. | 1.6 | 1 |
| 83 | Is there ageism in prostate cancer detection?. <i>Canadian Urological Association Journal</i> , 2013, 3, 211. | 0.6 | 1 |
| 84 | Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review. <i>Canadian Urological Association Journal</i> , 2015, 9, 671. | 0.6 | 1 |
| 85 | Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4. | 0.4 | 1 |
| 86 | Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (¹⁸F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5553-5553. | 1.6 | 1 |
| 87 | Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 504-505. | 0.4 | 1 |
| 88 | Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Euro Urol</i> 2021;80:442-9. <i>European Urology</i> , 2021, 81, e51-e51. | 1.9 | 1 |
| 89 | Major role for 5-alpha reductase inhibitors in the aging male. <i>Canadian Urological Association Journal</i> , 2007, 1, 22. | 0.6 | 0 |
| 90 | Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , 2019, 13, E292-E299. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e17-191.e24. | 1.6 | 0 |
| 92 | Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521. | 3.1 | 0 |
| 93 | AUTHOR REPLY. Urology, 2021, 153, 155. | 1.0 | 0 |
| 94 | Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. UroOncology, 2002, 2, 93-94. | 0.1 | 0 |
| 95 | High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5. | 0.5 | 0 |
| 96 | Reply by Authors. Journal of Urology, 2019, 202, 1165-1165. | 0.4 | 0 |
| 97 | Reply by Authors. Journal of Urology, 2020, 203, 1093-1093. | 0.4 | 0 |
| 98 | Reply by Authors. Journal of Urology, 2020, 204, 1194-1194. | 0.4 | 0 |
| 99 | Reply by Authors. Journal of Urology, 2020, 204, 475-475. | 0.4 | 0 |
| 100 | The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. Canadian Urological Association Journal, 2021, 16, . | 0.6 | 0 |
| 101 | Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , . | 1.6 | 0 |
| 102 | Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , . | 1.6 | 0 |